Surrogate Unexpected But Still Positive Outcome for Biogen (BIIB) - Stifel
Tweet Send to a Friend
Stifel analyst Paul Matteis reiterated a Buy rating and $346.00 price target on Biogen (NASDAQ: BIIB) on the back of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
